Designing HCP engagement for the next normalLife sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic Share XDesigning HCP engagement for the next normalhttps://pharmaphorum.com/views-and-analysis/designing-hcp-engagement-for-the-next-normal/
Research predicts the post-COVID landscape for HCP engagementIQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks Share XResearch predicts the post-COVID landscape for HCP engagementhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/research-predicts-the-post-covid-landscape-for-hcp-engagement/
A year on: pandemic driven trends in HCP engagementIQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in Share XA year on: pandemic driven trends in HCP engagementhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/a-year-on-pandemic-driven-trends-in-hcp-engagement-customer-experience/
Three pillars of post-pandemic launch excellenceIQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity Share XThree pillars of post-pandemic launch excellencehttps://pharmaphorum.com/views-and-analysis/three-pillars-of-post-pandemic-launch-excellence/
Unlocking health data to improve oncology outcomesAs the largest single-payer healthcare system in Europe, the UK’s National Health Service (NHS) has a uniquely beneficial Share XUnlocking health data to improve oncology outcomeshttps://pharmaphorum.com/r-d/views-analysis-r-d/unlocking-health-data-to-improve-oncology-outcomes-2/
Enabling new models of care: pursuing pharma’s partnership potentialThere is a huge, ongoing shift in how health and wellness is approached in the UK, and the Share XEnabling new models of care: pursuing pharma’s partnership potentialhttps://deep-dive.pharmaphorum.com/magazine/patients-and-partnerships-2020/enabling-new-models-of-care-pursuing-pharmas-partnership-potential/
Nine for 2021: The COVID-19 legacyIn the first of a two part series, IQVIA’s Sarah Rickwood covers nine key trends and events that Share XNine for 2021: The COVID-19 legacyhttps://pharmaphorum.com/views-and-analysis/nine-for-2021-the-covid-19-legacy/
UK initiative aims to cut COVID-19 drug development to a few weeksA new UK trial initiative aims to cut the design phase of clinical studies for potential COVID-19 drugs from around 18 Share XUK initiative aims to cut COVID-19 drug development to a few weekshttps://pharmaphorum.com/news/uk-initiative-aims-to-cut-covid-19-drug-development-to-a-few-weeks/
Unlocking health data to improve oncology outcomesThe NHS’ globally unique health data ecosystem has the potential to improve health outcomes. With around 363,000 new Share XUnlocking health data to improve oncology outcomeshttps://pharmaphorum.com/oncology/unlocking-health-data-to-improve-oncology-outcomes/
